Dr Annalisa Morgan reflects on new data on DMTs for RRMS that highlighted the potential of BTK inhibitors such as ...
A new analysis provides substantial evidence that paramagnetic rim lesions drive disability in MS and are targetable with a ...
Tolebrutinib is more effective in reducing the risk of disability progression in MS patients with paramagnetic rim lesions, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback